No material or nonsubstantive change to a currently approved collection
No
Regular
Approved without change
08/05/2020
08/03/2020
table that charts list comparision
Inventory as of this Action
Requested
Previously Approved
03/31/2022
03/31/2022
03/31/2022
445
0
262
2,761
0
131
0
0
0
This information collection supports implementation of the Food and Drug Administration (FDA, us or we) Prescription Drug User Fee program. Under the prescription drug user fee provisions of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (sections 735 and 736 (21 U.S.C. 379g and 379h)), as amended, we have the authority to assess and collect user fees for certain new drug applications (NDAs) and new biologics license applications (BLAs)
US Code:
21 USC 379
Name of Law: Federal Food Drug and Cosmetic Act
We are consolidating related information collection activity pertaining to prescription drug user fees for efficiency of agency operations. Upon approval we plan to discontinue control no. 0910-0693.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.